Drugs / BNT163
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05432583 | Dec 2022 → Oct 2026 expected | genital herpes simplex type 2 infectious disorder | BioNTech SE | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-12-21 | BioNTech SE | BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163 biontech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT163 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05432583 ↗ |
| Modality | Vaccine | “Anti-viral ribonucleic acid (RNA) vaccine” NCT05432583 ↗ |
| Route | Intramuscular | “administered as intramuscular injection” NCT05432583 ↗ |